Baird analyst Brian Skorney raised the firm’s price target on Neurocrine (NBIX) to $166 from $151 and keeps an Outperform rating on the shares. The firm updated its model following the company’s announcment of buying Soleno Therapuetics (SLNO) for $53 per share.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences: Vykat XR Acquisition Unlocks Diversified Growth and Upside Potential Despite Near-Term Pipeline Lull
- Neurocrine price target raised to $220 from $192 at Oppenheimer
- Midday Fly By: Neurocrine to acquire Soleno, Oracle hires new CFO
- Neurocrine’s Soleno Acquisition: Accretive Rare-Disease Expansion Supporting Long-Term Growth and Buy Rating
- Morning Movers: Soleno pops, Neurocrine dips after acquisition agreement